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9 ABSTRACT: The integrity and function of the periodontium can be
10 compromised by traumatic injuries or periodontitis. Currently available
11 clinical therapies are able to stop the progression of periodontitis and
12 allow the healing of periodontal tissue. However, an optimal strategy
13 capable of restoring the anatomy and functionality of the lost periodontal
14 tissue is still to be achieved. Herein is proposed the development of an
15 injectable hydrogel system able to release a growth factors and cells to the
16 periodontal defect. This injectable system is based on a photo-cross-
17 linkable hydrogel, prepared from methacrylated hyaluronic acid (me-HA)
18 and incorporating platelet lysate (PL). The delivery of growth factors and
19 cells in situ is expected to enhance regeneration of the periodontium.
20 Various formulations of me-HA containing increasing PL concentrations
21 were studied for achieving the formation of stable photo-cross-linkable
22 hydrogels. The produced hydrogels were subsequently characterized to
23 assess mechanical properties, degradation, protein/growth factor release proﬁle, antimicrobial activity and response toward
24 human Periodontal Ligament ﬁbroblasts (hPDLFs). The results demonstrated that it was possible to obtain stable photo-cross-
25 linkable hydrogels incorporating diﬀerent amounts of PL that can be released in a sustained manner. Furthermore, the
26 incorporation of PL improved (p < 0.02) the viscoelastic properties of the hydrogels and enhanced their resilience to the
27 degradation by hyaluronidase (HAase). Additionally, the PL was shown to provide antimicrobial properties. Finally, hPDLFs,
28 either seeded or encapsulated into the developed hydrogels, showed enhanced proliferation over time (p < 0.05), proportionally
29 to the increasing amounts of PL present in the hydrogel formulations.
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31 ■ INTRODUCTION
32 The periodontium is a complex and dynamic oral structure
33 comprising soft and hard tissues, the cementum, a functionally
34 oriented periodontal ligament, alveolar bone and gingiva The
35 main function of this structure is anchoring the teeth to the jaw
36 bones, while withstanding the forces originated by the
37 masticatory process.1 The integrity and function of the
38 periodontium can be compromised by trauma or disease,
39 such as periodontitis, an inﬂammatory disease predominantly
40 caused by Gram-negative bacteria that causes the destruction of
41 these tooth supportive tissues potentially leading to tooth
42 loss.1,2
43 Current therapeutic options, which include the implantation
44 of autografts, synthetic bone ﬁllers and guided tissue
45 regeneration (GTR), are not able to fully regenerate
46 periodontium morphology and function. In recent years
47 endogenous regenerative technology (ERT) has arisen as a
48 new paradigm in periodontal regeneration. This new concept
49 has its foundations in tissue engineering and aims to induce or
50encourage periodontal regeneration by superimposing speciﬁc
51chemical (e.g., growth factors) and biophysical cues.3 These
52signals are expected to encourage homing of stem and
53progenitor cells, leading to the formation of new periodontal
54ligament and cementum.3
55Platelet-rich hemoderivatives (PRHds), namely platelet-rich
56plasma and platelet-rich ﬁbrin, have been widely investigated
57for periodontal ERT as important sources of autologous growth
58factors and provisional ﬁbrin matrices.1,3 Nevertheless, the
59traditional PRHds clots retract, impairing the needed stability
60for periodontal tissue ingrowth.4 In this research work we
61propose the development of photo-cross-linkable hyaluronic
62acid hydrogels enriched with platelet lysate as a stable system
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63 for the delivery of endogenous GFs, directed for periodontal
64 ERT.
65 It is advocated that current ERT scaﬀolding materials needs
66 sophistication and that should be employed in a patient-tailored
67 fashion using preferably own patients’ biological material.3 In
68 this sense, platelet lysate (PL) oﬀer great potential in
69 regenerative medicine as an alternative source of growth factors
70 (GFs).5,6 These PL-origin GFs, include ﬁbroblast growth factor
71 (FGF), vascular endothelial growth factor, platelet-derived
72 growth factor, transforming growth factors-β1 and -β2, insulin-
73 like growth factor, epidermal growth factor, epithelial cell
74 growth factor, hepatocyte growth factor, and bone morphoge-
75 netic proteins7−9 are known to be involved in essential stages of
76 wound healing and regenerative processes such as chemotaxis,
77 cell proliferation and diﬀerentiation.10,11 Moreover, platelets
78 release numerous cell adhesion molecules (ﬁbrin, ﬁbronectin,
79 and vitronectin) which can provide a provisional matrix for the
80 adhesion and migration of cells.10 In addition, platelet
81 concentrates (PCs) have also been reported to exhibit
82 antimicrobial properties12 and the PL, as a product of PCs
83 activation, is expected to have the same antimicrobial
84 properties, contributing for the prophylaxis of the wound site.
85 In fact, the use of PL holds several advantages over other
86 PRHds, which include the ease of standardizing the production
87 process and the higher consistency in GF content between
88batches,5 that is expected to yield more predictable clinical
89outcomes.
90Because PL is obtained as a liquid solution, it was
91incorporated in a photo-cross-linkable HA matrix. HA is a
92glycosaminoglycan copolymer of D-glucuronic acid and N-
93acetyl-D-glucosamine that is present in connective tissues and
94plays an important role in several cellular processes including,
95cell proliferation, morphogenesis, inﬂammation, and wound
96repair.13 HA-based biomaterials have demonstrated positive
97results for several potential applications in the regeneration of
98hard or soft tissues.14 Moreover, given HA anti-inﬂammatory,
99antiedematous, and antibacterial eﬀects, it has been also
100proposed for the treatment of lesions caused by periodontal
101diseases.15−17
102The aim is to characterize these PL-rich scaﬀolds with regard
103to mechanical properties, release of proteins, periodontal cell
104response, and antimicrobial action against dental plaque
105bacteria. This new ERT scaﬀold oﬀers a new and promising
106periodontal treatment modality that should encourage tissue
107regeneration through the release of PL-derived GFs while
108providing concomitant antimicrobial action. Furthermore,
109functionalization of HA with methacrylic groups allows the
110production in situ of stable photopolymerizable hydrogels,
111enabling the application in periodontal defects in a clinical
112scenario.
Figure 1. (A) Scheme of the methacrylation process of Hyaluronic acid using methacrylic anhydride. (B) Representative image depicting a typical
me-HA/PL hydrogel obtained by photopolimerization. (C) FTIR Spectra of HA and me-HA produced with 5 and 10× molar excess of (5× and 10×
me-HA). (D) 1HNMR spectra of HA, 5× me-HA and 10× me-HA: (a) vinyl groups of MA (δ 5.77−6.20 ppm); (b) methyl group of the N-acetyL-
D-glucosamine (δ 2.05 ppm); and (c) methyl group of MA (δ 1.94 ppm).
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113 ■ MATERIALS AND METHODS
114 Materials. HA obtained from Streptococcus equi (Mw = 1.5 to 1.8
115 MDa), methacrylic anhydride Irgacure 2959 (2-hydroxy-4-(2-hydrox-
116 yethoxy)-2-methylpropiophenone), hyaluronidase type IV from bovine
117 origin (HAase), phosphate buﬀered saline (PBS), phalloidin-
118 tetramethylrhodamine B isothiocyanate 4,6-diamidino-2-phenylindole,
119 dilactate (DAPI) and the dialysis tubing cellulose membrane were all
120 purchased from Sigma (Sigma-Aldrich, USA). Sodium hydroxide
121 (NaOH) and hydrochloride acid (HCl) were purchased from VWR
122 Chemicals (BDH, Prolabo - international, USA). Alpha MEM (α-
123 MEM) culture medium and fetal bovine serum (FBS) were purchased
124 from Gibco (Life Technologies, UK). Deuterium oxide (2H2O) was
125 purchased from LaborSpirit lda (PT) and the polydimethylsiloxane
126 (PDMS) from Down Corning (USA). The Muller−Hinton agar plate
127 was obtained from Oxoid (UK).
128 Preparation of Platelet Lysate (PL). PL was obtained from
129 diﬀerent lots of platelet concentrates provided by Servico̧ de
130 Imunohematologia do Centro Hospitalar de Saõ Joaõ (CHSJ, Porto,
131 Portugal), based on a previously established protocol. To produce PL,
132 batches of platelet concentrates obtained by plasma apheresis with a
133 density of 106 cells/μL and biologically qualiﬁed according to
134 Portuguese legislation (Decreto-Lei No. 100/2011) were processed
135 as previously described.18,19 Very brieﬂy, platelet concentrates from
136 three diﬀerent donors were pooled and exposed to three repeated
137 freezing and thaw cycles (frozen with liquid nitrogen and thawed in a
138 37 °C water bath) to promote the lysis of the platelets and release of
139 GFs. Afterward, the lysis product was centrifuged at 1400 rcf for 10
140 min and the supernatant stored at −20 °C until further use.18,19
141 Methacrylation of Hyaluronic Acid (HA). The method followed
142 for the methacrylation of HA was based on a previously described
f1 143 protocol,20 (depicted in Figure 1A), consisting in the addition between
144 5- to 10-fold molar excess (5× and 10×) of methacrylic anhydride
145 (MA) to a solution of 1 wt % HA in distilled water (dH2O). The pH
146 was adjusted between 8 and 8.5 with 5N NaOH added dropwise. The
147 reaction occurred during 24 h at 4 °C provided by an ice bath.
148 Subsequently, the reaction products were precipitated using cold
149 ethanol (at −20 °C). Then the precipitate was dissolved in dH2O and
150 dialyzed using a membrane with a cutoﬀ of 14 000 kDa for a week
151 against mili-Q water, replaced 3 times a day, to remove the unreacted
152 reagents and byproducts. Finally, the solution was ﬁltered, frozen at
153 −80 °C and the methacrylated HA (me-HA) recovered upon
154 lyophilization.
155 Characterization of the me-HA. Fourier transform infrared
156 spectroscopy (IR-Prestige-21, FTIR Shimadzu) was used to record the
157 infrared spectra of HA and me-HA. Brieﬂy, a small portion of each
158 batch was mixed with potassium bromide, and processed into pellets.
159 The spectra were obtained in the range of 400 to 4000 cm−1 at a 4
160 cm−1 resolution with 32 scans. 1HNMR spectra were recorded with a
161 Varian Inova 500 at 70 °C. me-HA solutions were prepared for
162 analysis by dissolving 5 mg of me-HA in 1 mL of 2H2O. The degree of
163 methacrylation (Dmet) was deﬁned as the percentage of methacryloyl
164 groups per HA disaccharide repeat unit and was calculated from the
165 ratio of the relative peak integration of the methacrylate protons
166 (peaks at ∼6.20, ∼ 5.77, and ∼2.05 ppm) and HA’s methyl protons
167 (∼1.98 ppm).
168 Development of the Photo-cross-linkable me-HA Hydrogels
169 Incorporating PL. The development of the photo-cross-linkable me-
170 HA hydrogels incorporating PL was optimized by changing the HA
171 (5x and 10x MA molar excess) solution concentration (1 and 2 wt %),
172 the concentration of photoinitiator Irgacure 2959 (0.1 and 0.2 wt/v%),
173 the power of the UV light, the distance to the UV light source, and the
t1 174 concentration of PL incorporated in the solvent solution (Table 1). PL
175 was incorporated in the solvent solution in increasing volumetric
176 concentrations ranging from pure water (0% PL) to pure PL (100%
177 PL). To obtain hydrogels, dry me-HA was dissolved in the solvent
178 solution containing the photoinitiator. Then, 25 μL of me-HA solution
179 were injected into a circular (5 mm diameter) PDMS mold and
180 exposed to a UV light (Omnicure series 2000 EXFO S2000-XLA,
181 Omnicure, Canada) to trigger the photo-cross-linking, producing disk-
182shaped hydrogels. The produced formulations, incorporating 0, 50 and
183100% PL, were designated PL0, PL50, and PL100, respectively.
184Characterization of the HAPL Hydrogels. Only the 10× me-
185HA batch allowed obtaining the hydrogels by photopolymerization,
186using either 0.1 or 0.2% of photoinitiator, so this batch was selected for
187all further studies. Considering that Igacure 2959 presents some
188cytotoxicity,21 it was also decided to use the lower photoinitiator
189concentration for the following characterization steps.
190Evaluation of the Mechanical Properties by DMA. The
191viscoelastic properties of the developed hydrogels (PL0, PL50, and
192PL100 with 1% or 2% of me-HA and with 0.1% of Irgacure) were
193evaluated by dynamic mechanical analysis (DMA) (TRITEC8000B,
194Triton Technology, UK), equipped with the compressive mode. DMA
195spectra were obtained during a frequency scan ranging between 0.1
196and 15 Hz for all time points. The experiments were performed under
197constant strain amplitude, corresponding to approximately 1% of the
198original height of the sample. Samples were tested while immersed in
199PBS and at 37 °C, to simulate the physiological conditions.
200Swelling and Weight Loss. The results obtained from the DMA
201analysis revealed better mechanical properties for the 2% me-HA
202formulation and thus this was selected for the subsequent studies,
203namely degradation, protein release and cell response. Thus,
204formulations of hydrogels with increasing concentrations of PL (PL0,
205PL50 and PL100), were prepared into disc-shaped samples of 5 mm in
206diameter and 1 mm thickness, as above-described, and placed in 24
207wells plate.
208Periodontal ligament ﬁbroblasts express hyaluronidase (HAase) and
209generate HAase activity that regulates extracellular hyaluronan
210metabolism.22 Given the presence of this enzyme in the periodontium,
211the degradation promoted by a HAase was investigated. Similar assay
212was conducted in PBS. Each sample was incubated in 1.6 mL of PBS at
21337 °C, pH 7.4. For the enzymatic degradation assays, the same
214formulations were incubated at 37 °C in 1.6 mL of a HAase solution of
215100 U/mL in PBS.
216The assays were carried out using 4 samples of each formulation
217immersed in each of the solutions. The samples were retrieved after 1,
2183, 7, 14, and 21 days of incubation.
219The wet weight of the samples was registered (PI-214 analytical
220balance, Denver Instrument Company, USA) at each predetermined
221time point. The dry weight of the samples was also registered after
222allowing samples to dry overnight at 37 °C. The percentage of weight
223loss was calculated according to eq 1
= −m m
m
weight loss
( )
100i f
i 224(1)
Table 1. Summary of the Formulations Studied for the
Optimization of the Hyaluronic Acid Hydrogels
Incorporating PL (HAPL)a
me-HA (wt/v%) Irgacure (wt/v%) PL (v/v%)
1 0.10 0
50
100
0.20 0
50
100
2 0.10 0
50
100
0.20 0
50
100
aThe concentrations of me-HA and Irgacure 2959 are presented as
weight/volume percentage. The PL concentrations are volumetric
concentrations of pure PL (100%PL) in water (0%PL). All the
formulations were prepared using both the batches of me-HA (5× and
10× molar excess).
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225 where mi is the initial weight and mf the ﬁnal weight.
226 The water uptake ratio was also calculated following eq 2 by
227 dividing each sample wet mass (mwet) by the ﬁnal dry hydrogel mass
228 (mdry).
= m
m
water uptake ratio 100wet
dry229 (2)
230 Quantiﬁcation of Protein Release. Protein release from PL0,
231 PL50 and PL100 was quantiﬁed after 30 min, 1, 4, and 8 h, and 1, 7, 14,
232 and 21 days of incubation in PBS at 37 °C. For this purpose, at each
233 time point, a volume of supernatant was collected and stored at −20
234 °C. The total protein content was quantiﬁed using a micro BCA
235 protein assay (Thermo Fischer Scientiﬁc, USA), following the
236 manufacturer’s instructions. Additionally, the release of ﬁbroblast
237 growth factor-2 (FGF-2), present in the PL, was also quantiﬁed using
238 an enzyme-linked immunosorbent assay kit (Human FGF-basic,
239 ELISA Development Kit, by PeproTech, USA), according to
240 manufacturer’s instructions.
241 Evaluation of the Response of Human Periodontal
242 Ligament Fibroblasts (hPDLFs). The response of hPDLFs to the
243 photo-cross-linked me-HA/PL hydrogels was assessed upon either
244 encapsulation or seeding of the cells onto the hydrogels surface and
245 further cultured for up to 14 days.
246 The hPDLFs (ScienCell Research Laboratories) at passage 3 were
247 seeded on disc-shaped (5 mm diameter) samples of the formulations
248 PL0, PL50, and PL100 produced as previously described, at a cell density
249 of 5 × 104 cm−2. A 50 μL drop of a cellular suspension containing 1 ×
250 104 cells was seeded on the surface of each sample, previously placed
251 in a 24 wells plate, and allowed to adhere for 1 h. After this period, 450
252 μL of α-MEM basal medium (supplemented with 10% of FBS and 1%
253 antibiotic-antimycotic) were added to each well. The 24 wells plates
254 containing the cell-seeded hydrogels were further incubated at 37 °C,
255 5% CO2 for 1, 4, 7, and 14 days, renewing the culture medium every 3
256 days. Cells cultured on polystyrene coverslips (Sarstedt) were
257 employed as positive control.
258 For the encapsulation, hPDLFs cells were resuspended in 2% me-
259 HA solutions containing 0, 50 and 100% PL to obtain a ﬁnal cell
260 density of 4 × 106 cells mL−1. Then, 25 μL (1 × 105 cells) of the
261 cellular suspension in each hydrogel solution formulation was injected
262 into circular molds (5 mm diameter) and exposed to UV light, as
263 previously described to obtain the hydrogel samples. The cell-laden
264 hydrogels were subsequently transferred to individual wells of 24-well
265 plates, each one containing 500 μL of basal medium. The 24-wells
266 plates were incubated at 37 °C, 5% CO2 for 1, 4, 7, and 14 days
267 renewing the culture medium every 3 days.
268 The metabolic activity of the cells seeded/encapsulated in the
269 hydrogels and further cultured was evaluated using the Alamar blue
270 assay (AbDseroTec, USA), following the manufacturer’s instructions.
271 Brieﬂy, at each time point, the culture medium was discarded, the
272 samples were washed twice with PBS and then incubated in a 10%
273 Alamar blue solution in basal medium (450 μL of basal medium, and
274 50 μL of Alamar blue) at 37 °C, 5% CO2 for 150 min. The
275 ﬂuorescence of the supernatant solution was read in triplicates in a
276 microplate reader (Synergy HT, Biotek, USA) at 560 nm of excitation
277 and 590 nm of emission.
278 The cellular proliferation was also evaluated as a function of the
279 dsDNA quantiﬁcation using the PicoGreen dsDNA quantiﬁcation kit,
280 according to manufacturer’s speciﬁcations (Life Technologies, USA).
281 Finally, the morphology and the migration of the cells either
282 encapsulated or seeded on the surface of the hydrogels were
283 investigated by confocal microscopy, upon staining with DAPI and
284 phalloidin. For this purpose, samples retrieved after each of the preset
285 culturing times were ﬁxed with 10% formalin (in PBS) for 30 min at
286 room temperature. Afterward, the samples were washed 2 times with
287 PBS to remove the formalin and 300 μL of phalloidin solution (1:100
288 in PBS) were added per well and incubated 1 h at room temperature.
289 Then phalloidin solution was discarded and the samples were washed
290 3 times with PBS. A DAPI solution (1:1000 in PBS) was prepared and
291 300 μL were added per well and incubated 5 min. The samples were
292 washed 3 times and the prepared for visualization under a confocal
293microscopy (TCS SP8 from Leica Mycrosystems CMS GmbH) with
294Vectashield mounting medium.
295Antimicrobial Assay. The antimicrobial activity of PL soluble
296factors released form from the HA hydrogels was evaluated using the
297radial diﬀusion assay, according to Kirby-Bauer method.23 Five
298diﬀerent bacteria species were used: the Gram-positive bacteria
299Bacillus megaterium (Internal collection), Methicillin Resistant Staph-
300ylococcus aureus (MRSA) (Internal collection), and Vancomycin
301Resistant Staphylococcus aureus (VRSA) (internal collection) and the
302Gram-negative species Pseudomonas aeruginosa T6BT12, Escherichia
303coli DH5α) and the fungus Candida albicans (Internal collection).
304With the exception of P. aeruginosa, which was isolated from
305environmental samples, all the other microorganisms were isolated
306from clinical samples. Prior to the antimicrobial activity testing, these
307microorganisms were cultured aerobically in Luria−Bertani broth at 37
308°C overnight with agitation (150 rpm). Afterward, they were
309centrifuged at 8000 rpm for 5 min, and washed three times with
310PBS. Microbial cultures were adjusted to a concentration correspond-
311ing to ca. 1 ×107 CFU mL−1, and pipetted with 0.4% agar into a Petri
312dish containing 5 mL of Muller-Hinton (MH) Agar plate.
313The PL0, PL50 and PL100 hydrogels and the negative control (PBS)
314were placed on MH−agar plates and cultured with each of microbial
315strain at 37 °C for 16 h, upon which the inhibition halo measure and
316the general macroscopic response was recorded. Experiments were
317performed in triplicate.
318Statistical Analysis. All the experiments were performed with at
319least three replicates. All the cell culture experiments were performed
320simultaneously in order to reduce the variability intra-assay and 3
321independent studies were performed, exactly as described. Results are
322expressed as mean ± standard error of the mean (SEM). Statistical
323analysis was performed by repeated measures Two-way ANOVA
324comparison test (* p < 0.05, ** p < 0.01 and *** p < 0.001 for
325statistically signiﬁcant diﬀerences) using the software Graph Pad Prism
3266.
327■ RESULTS
328Development of the Photo-cross-linkable me-HA
329Hydrogels. HA methacrylation. In this study, unmodiﬁed
330hyaluronan was methacrylated Reacting a 1% HA aqueous
331solution at pH 8, with 5× and 10× of molar excess of MA for
33224h at 4 °C.
333The methacrylation of HA was conﬁrmed by the FTIR
334spectra, where the deep peak at 1715 cm−1 represents the
335carbonyl ester group resultant from the methacrylation (Figure
3361C). Moreover, the 1HNMR spectra of the me-HA batches
337(Figure 1D) exhibited the presence the characteristic peaks
338corresponding to the two protons of the double bond region (δ
3395.77 and 6.20 ppm) of the MA group absent in the
340nonmodiﬁed HA spectrum.
341The degree of methacrylation was calculated from the ratio
342of the relative peak integration of the methacrylate protons
343(peaks at ∼6.20, ∼5.77, and ∼2.05 ppm) and the methyl
344protons of N-acetyl-D-glucosamine (∼1.98 ppm). A Dmet of
34514% was obtained for the me-HA batch produced with 5×
346excess of MA (5× me-HA), while the batch produced with 10×
347excess MA (10× me-HA) presented a Dmet of 24%.
348Mechanical Properties of the Developed Hydrogels.
349Dynamic mechanical analysis (DMA) experiments were
350performed in a hydrated environment at 37 °C, in an array
351of biologically relevant frequencies, in order to assess the
352viscoelastic properties of the samples in a physiological-like
353environment. Both storage (elastic) modulus, E′, and the loss
354factor, tan δ, were obtained at diﬀerent frequencies. E′ is a
355measure of the materials stiﬀness. The loss factor is the ratio of
356the amount of energy dissipated (viscous component) relative
357to energy stored (elastic component); tan δ = E′/E″.
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f2 358 The obtained results (Figure 2) showed the eﬀect of diﬀerent
359 concentrations of me-HA and/or PL on the stiﬀness of the
360developed hydrogels. When the concentration of me-HA was
361increased from 1% to 2% the elastic storage modulus of the
Figure 2. Variation in (A) elastic modulus (E′) and (B) loss factor (tan δ) with frequency of 1% and 2% HA hydrogels incorporating 0, 50, and
100% v/v PL (PL0, PL50, and PL100) measured by dynamic mechanical analysis. Diﬀerences observed on (C) elastic modulus (E′) and (D) loss factor
(tan δ) at 1 Hz. * p < 0.05, ** p < 0.02; *** p < 0.001.
Figure 3. Weight loss (A, B) and (C, D) swelling ratio proﬁle of PL0, PL50, and PL100 hydrogels in (A, C) PBS and (B, D) HAase solution (100 U/
mL). (a) Statistically diﬀerent (p < 0.05) from PL100; (b) statistically diﬀerent (p < 0.05) from PL50; (c) statistically diﬀerent (p < 0.05) from PL0 and
PL50.
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362 hydrogels also increased above three to four times, from
363 approximately 100 kPa to 428−600 kPa, in formulations
364 incorporating PL (PL50 and PL100). The concentration of PL in
365 the hydrogels also showed to inﬂuence the elastic modulus that
366 was found to increase proportionally with the amount of PL.
367 The formulation that exhibited the highest elastic modulus
368 corresponds to the formulation containing 2% of me-HA
369 dissolved in 100% PL.
370 Degradation Behavior. The weight loss and swelling ratio
371 proﬁles of the PL0, PL50 and PL100 hydrogels after incubation in
372 PBS or HAase (100U/mL) solution at 37 °C for 1, 3, 7, and 14
f3 373 days are presented in Figure 3.
374 Weight Loss. Overall, the results obtained showed that the
375 incorporation of PL in me-HA hydrogels inﬂuences its stability.
376 Although the PL0 hydrogels showed lower weight loss until the
377 seventh day of immersion in PBS, they were completely
378 degraded after 14 days (Figure 3A). On the other hand, despite
379 the weight loss proﬁle of the formulations incorporating PL is
380 characterized by an initial loss of around 70% of the dry weight
381 in the ﬁrst 3 days, the PL50 and PL100 hydrogels tend to be
382 more stable along immersion time in PBS.
383 The weight loss results obtained upon immersion in HAase,
384 revealed that PL100 formulation displays higher degradability,
385 upon the ﬁrst day. Nevertheless, it was found that samples
386 containing PL were only completely degraded after 14 days,
387 while all the hydrogels of the PL0 formulation were completely
388 degraded after only 3 day of immersion in the enzymatic
389 solution.
390 Swelling Ratio. In the beginning of the assay, the swelling of
391 freshly produced PL100 hydrogels was signiﬁcantly lower than
392 the formulations with lower PL concentration. When immersed
393 in the PBS solution the PL0 and PL50 hydrogels, did not show
394 signiﬁcant statistical diﬀerences among them for all the time
395 points studied. Accordingly, both hydrogels formulations
396 presented a similar proﬁle characterized by a peak around day
397 1 (1500% for PL50) and day 3 (1000% for PL0), followed by a
398 decrease of swelling until the end of the assay, because of the
399 total degradation of the material. On the other hand, PL100
400 hydrogels had a later peak at day 7, reaching near 1400% of
401 swelling.
402 Regarding the swelling in HAase solution, the values were
403 statistically similar for PL0, PL50 and PL100 hydrogels.
404 Nevertheless, while the formulations PL0 and PL50 depicted a
405 similar behavior, presenting a constant decrease in the swelling
406 values from the beginning of the assay, the PL100 formulation
407 reached an average swelling of 1400% at day 7, before starting
408 to decrease.
409 Protein Release. The total amount of protein released from
f4 410 me-HA/PL hydrogels over time is represented in Figure 4.
411 Both PL50 and PL100 hydrogels displayed a similar release
412 proﬁle that is characterized by an initial “burst” of protein
413 released during the ﬁrst hour, that represents around 15% for
414 PL100 hydrogels and 25% for PL50 hydrogels of the total protein
415 contained, followed by a sustained release up to 14 days.
416 Although no statistically signiﬁcant diﬀerences were observed
417 between the formulations during the ﬁrst day of release, there
418 was a substantial diﬀerence in the amount of protein released
419 by the PL100 formulation, which is proportional with the
420 amount of protein incorporated in the formulations.
421 To evaluate the release of PL-speciﬁc GFs from the
422 developed HA hydrogels, and the interaction of the GFs with
423 the HA mesh, hydrogels were incubated either in PBS or in 100
424U/mL HAase solution and the release products were quantiﬁed
425by ELISA.
426The results for the release of FGF-2, depicted in Figure 4B,
427showed that the PL50 and PL100 had a diﬀerent proﬁle for FGF-
4282 release. The FGF-2 released by PL50 was characterized by an
429initial burst of release up to day 3, as observed. After day 3, the
430release kinetics reached an apparent plateau, and a slow
431sustained delivery remained up to day 21. On the other hand,
432PL100 hydrogels showed a sustained release, progressing in a
433linear way, during all the duration of the assay, without signs of
434deceleration. Nevertheless, despite the PL100 hydrogels have
435higher amount of total protein incorporated, they depicted a
436FGF-2 release similar to the PL50 hydrogel.
437Cell Response to the Developed Hydrogels. The response
438of hPDLFs, either surface seeded or encapsulated onto the PL0,
439PL50 and PL100 hydrogels was assessed. In both the cases, the
440increasing amounts of PL in the hydrogels had a positive eﬀect
441in the cells metabolic activity and proliferation rate as shown in
442 f5Figure 5.
443The results presented in Figure 5A show that there were no
444signiﬁcant diﬀerences between the PL0 and PL50 hydrogels with
445respect to proliferation and metabolic activity of encapsulated
446cells. Remarkably, PL100 hydrogels exhibited higher cell growth
447and metabolic activity than PL0 and PL50 hydrogels. Regarding
448the morphology of the encapsulated cells, Figure 5B shows that
449hPDLFs dispersed and stretched inside of the hydrogels,
450following the alignments of the ﬁbrous structures observed
451macroscopically in the hydrogels.
452The Figure 5C shows the behavior of the hPDLFs cells when
453seeded at the surface of the PL0, PL50 and PL100 hydrogels. No
Figure 4. Total protein released from the hydrogels containing PL,
(A) assessed using the Pierce BCA protein assay kit incubated in PBS.
Fibroblasts growth factor (FGF) release, (B) assessed using the
PeproTech ELISA development kit incubated in HAase solution (100
U/mL). ** p < 0.02; *** p < 0.001.
ACS Biomaterials Science & Engineering Article
DOI: 10.1021/acsbiomaterials.6b00508
ACS Biomater. Sci. Eng. XXXX, XXX, XXX−XXX
F
454 signiﬁcant diﬀerences were seen in terms of seeding eﬃciency
455 on the hydrogels and on the PS positive control.
456 The analysis of hPDLFs distribution throughout the PL-
457 enriched hydrogels, obtained by confocal microscopy from
458 PL100 hydrogels 21 days after being seeded on the surface, is
f6 459 represented in Figure 6. This picture shows that hPDLFs
460 seeded in the surface of the hydrogels migrated up to 70 μm
461 deep into to the hydrogel after 21 days in culture.
462 Antimicrobial Activity. The antimicrobial eﬀect of PL
463 soluble factors against Pseudomonas aeruginosa, Candida
464 albicans, Escherichia coli, Bacillus megaterium, Staphylococcus
465 (VRSA), and Staphylococcus (MRSA) was evaluated.
466 The antimicrobial properties of the developed hydrogels
467 containing PL were assessed using the agar well diﬀusion
468 method, adapted from the Kirby-Bauer original method for
f7 469 testing microbial resistance to antibiotic drugs. The Figure 7
470 shows the eﬀect of the hydrogels incorporating increasing
471 amounts of PL in the Pseudomonas aeruginosa, Candida albicans,
472and Escherichia coli and, Bacillus megaterium, vancomycin-
473resistant Staphylococcus aureus (VRSA), and methicillin-
474resistant Staphylococcus aureus (MRSA).
475The release of PL provides antimicrobial action against
476methicillin resistant Staphylococcus aureus, as shown by the
477inhibition of growth in the space occupied by the PL100
478hydrogel (Figure 7F). Moreover, it is dependent on the PL
479content, because no inhibition hallo was observed for the
480formulations with lower amounts of PL incorporated (PL0 and
481PL50). Nevertheless, despite no inhibition halo was observed in
482the rest of the species for the formulations investigated, no
483degradation or bacterial growth on the hydrogel surface was
484reported.
485■ DISCUSSION
486The present work describes the development of novel photo-
487cross-linkable hydrogels incorporating allogenic platelet lysate,
488a platelet rich hemoderivative (PRHd), aimed at endogenous
Figure 5. Response of hPDLFs seeded/encapsulated on the hydrogels with the formulations PL0, PL50, PL100.. (A) DNA quantiﬁcation and
metabolic activity of encapsulated cells. (B) DNA quantiﬁcation and metabolic activity of seeded cell. (C) Representative pictures of hPDLFs
encapsulated in PL50 and PL100 hydrogels, stained with DAPI (blue) and phalloidin (red). for 21 days. The small micrographs on the bottom left
depict the spindlelike shape morphology of the hPDLFs encapsulated into the hydrogels. (D) hPDLFs seeded on PL50 and PL100 hydrogels and
cultured for 21 days, stained with DAPI (blue) and Phalloidin (red).
Figure 6. Three-dimensional reconstruction obtained by confocal microscopy of hPDLFs distribution on PL100 hydrogels at day 21.
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489 regenerative technology (ERT) being used for the regeneration
490 of periodontal ligament. PL can be used in clinical applications
491 as an autologous therapy. However, several authors5,24 have
492 reported high donor-to-donor variability in PRHds batches,
493 which could correlate with the high variability associated with
494 the clinical outcomes of PRHds treatments.25 On the other
495 hand, Crespo-Diaz et al.5 reported lower variability in PL
496 batches produced from outdated platelet concentrates obtained
497 by plasma apheresis from diﬀerent donors; therefore more
498 predictable therapeutic outcomes could be anticipated.
499 Furthermore, these PL batches were shown to be safe of
500 standard pathogens and infectious diseases. In the present
501 work, were used outdated (>5 days old) platelet concentrates
502 obtained by plasma apheresis and biologically qualiﬁed
503 according to Portuguese legislation (Decreto-Lei No. 100/
504 2011) for blood products collection, transport and therapeutic
505 administration. Therefore, these PL batches are expected to be
506 as safe as any other blood component aimed for therapeutic
507 administration and used in allogenic PL-based strategy as
508 proposed. The combination of me-HA with PL, as herein
509 proposed, produced a photo-cross-linkable system with several
510 advantages for tissue engineering applications. Being injectable,
511 these biomaterials can be implanted using minimally invasive
512 techniques without requiring surgical interventions. Moreover,
513 the system can ﬁt perfectly to irregular-shaped defects, deeply
514 interacting with the preserved tissue margins, before being
515 photo-cross-linked to produce a stable matrix.
516 With regard to viscoelastic properties, DMA analysis revealed
517 that these hydrogels exhibit elastic modulus ranging from 264 ±
518 81 kPa for the PL0 formulation to 600 ± 186 kPa to the PL100
519 formulation (at 1 Hz), comparable to other HA hydrogels
520 incorporating ﬁbrin described for artiﬁcial cartilage implanta-
521 tion (445 kPa),26 which support the use of our photo-cross-
522 linkable hydrogels for soft tissue reconstruction. Moreover,
523 periodontal tissue is continuously subjected to very dynamic
524forces, acting the periodontal ligament as a damper.27,28
525Therefore, the viscoelastic properties displayed by the hydro-
526gels herein developed are of paramount importance for
527periodontal therapy approaches.
528Regarding the degradation of HA hydrogels, it was faster in
529the presence of the HAase, the speciﬁc enzymes that degrade
530the HA in vivo,29 than in saline solution, as previously
531reported.13,30 Remarkably, the PL-enriched hydrogels remained
532stable for longer periods. The time to total degradation of PL100
533was even longer when compared with other HA hydrogels
534exposed to similar conditions.13 It should be noted that in this
535study we used a supra-physiologic concentration of HAase (100
536U/mL), which in human plasma ranges from 0.0028 ± 0.0004
537U/L to 3.8 ± 0.7 U/L depending on patient health condition.31
538Therefore, these ﬁndings suggest that PL-enriched photo-cross-
539linkable HA hydrogels, may maintain the necessary space
540stability in vivo for new tissue ingrowth.4 Such reinforcement is
541attributed to the presence of ﬁbrinogen in the PL,1,18 as this
542protein is capable of cross-linking, forming a ﬁbrin mesh which
543is not susceptible to degradation by the HAase. The ﬁbrin/
544ﬁbrinogen interact speciﬁcally with HA for the formation of
545ECM either during wound healing or in normal tissues.32 This
546result is in line with previous studies in which HA hydrogels
547incorporating ﬁbrin were proposed for cartilage repair26 given
548their improved biomechanical properties and the ability to
549provide an adequate environment for cell encapsulation.
550The total PL-proteins release kinetics from the HA hydrogels
551herein developed was characterized by an initial “burst”,
552followed by a sustained release over time. The release proﬁle
553observed can be explained by two diﬀerent processes: (1) the
554fast elution of large amount of the soluble proteins that are not
555physically interacting with the HA mesh, facilitated by the
556strong initial swelling of roughly two times the hydrogel initial
557weight; (2) a slow release of the proteins entrapped in the
558hydrogel mesh or adherent to the mesh, that are released by the
Figure 7. Antimicrobial assay for (i) PL100, (ii) PL50, and (iii) PL0 formulations where control is (iv) PBS using (A) Pseudomonas aeruginosa, (B)
Candida albicans, (C) Escherichia coli (E. coli), (D) Bacillus megaterium, (E) vancomycin-resistant Staphylococcus aureus (VRSA), and (F) methicillin-
resistant Staphylococcus aureus (MRSA).
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559 physical degradation of the hydrogel. Since the PL proteins
560 have diﬀerent isoeletric points (pI), the electrostatic
561 interactions and probability of remaining adsorbed to the HA
562 mesh, which are negatively charged at physiologic pH, will vary.
563 In this way, the albumin, which is the main soluble protein in
564 PL,33 with an acidic pI (at pH 4.7), is expected to be easily
565 washed out from the HA mesh. On the other hand, most of the
566 GFs present in PL with therapeutic interest have basic pI
567 (TGF-β at pH 8.90; PDGF-A at pH 9.52; PDGF-B at pH 9.39;
568 VEGF-1 at pH 8.66; FGF-2 at pH 9.6). So, they are expected to
569 bind electrostatically to the HA matrix and to the insoluble PL
570 proteins to be further released by ion exchange or by the
571 degradation of the HA mesh promoted by HAses released for
572 the ECM remodeling promoted during the wound healing
573 process. In fact, the release of PL-speciﬁc GFs from the photo-
574 cross-linkable hydrogels, namely FGF-2, was detected only after
575 degradation of the hydrogels in HAase (Figure 4B), whereas no
576 detectable traces of GFs were detected after incubation of the
577 hydrogels in PBS. Studies with FGF-2 have shown that this GF
578 upregulate the migration and proliferation of PDL cells.34 In
579 fact, to fully regenerate functional of periodontal tissues, several
580 GFs and cytokines should interplay in a temporal as spatial
581 controlled manner.10 Therefore, the controlled release of
582 growth factors is a real asset to our hydrogels.
583 In line with what has been reported in literature, our ﬁndings
584 show that the encapsulation of hPDLFs in nonsupplemented
585 HA hydrogels (PL0) aﬀects cell proliferation and metabolic
586 activity. The biological performance of cells encapsulated in
587 me-HA hydrogels is aﬀected by the concentration of the
588 macromer,13,35 as well as by the concentration of photo-
589 initiator.35 Furthermore, the exposure to UV radiation was also
590 reported to have adverse eﬀects on viability and cell cycle
591 progression, whereas the diﬀerentiation potential remains
592 unchanged.35 Remarkably, the adverse eﬀects of photo-
593 encapsulation were overcome by the incorporation of PL into
594 the hydrogels. The viability and metabolic activity of the
595 encapsulated hPDLFs increased proportionally with the
596 incorporation of PL. Previous works have reported the positive
597 eﬀect of PL in the proliferation and maintenance of stemness
598 phenotype of human periodontal ligament stem cells.36 In the
599 same line, we observed, in previous works that (hPDLFs)
600 adhere and proliferate in genipin-cross-linked PL membranes.37
601 It is known that platelets release several growth factors, namely
602 PDGF and FGF-2, which have a mitogenic eﬀect over human
603 periodontal ligament cells.38,39 Moreover, PDGF and FGF-2
604 have been reported to have chemotactic properties over
605 hPDLFs,34,40 while the adhesion sites provided by the clot-
606 forming proteins present in PL should facilitated the inward cell
607 migration observed (Figure 6). Therefore, a strategy that can
608 recruit progenitor cells from the preserved periodontal tissue
609 and promote their proliferation and maintenance of stemness
610 to colonize the periodontal defect with cells with great potential
611 to regenerate periodontal tissue would be a valuable asset for
612 periodontal ERT. Hereupon, the ﬁrst intentional repair
613 promoted by cells originated from periodontal tissues could
614 partially restore the primitive anatomy and function of the
615 periodontium.4
616 Finally, we have studied the antimicrobial properties of the
617 developed hydrogels, a very important aspect considering the
618 target application. It is known that the main cause of
619 periodontal disease, as well as the main factor of rejection for
620 some of the GTR techniques, is bacterial infections.41,42 The
621 HA was previously described to have bacteriostatic properties
622against oral and nonoral bacteria.43 Carlson et al.43 suggested
623that the bacteriostatic eﬀect of HA may be due to the saturation
624of the bacterial hyaluronate lyase by the excess HA, which
625prevents the bacteria from maintaining elevated levels of tissue
626permeability and penetrating the physical defenses of the host.
627This would enhance the ability of the host’s immune system to
628eradicate pathogens. HA molecules in the hydrogels also form a
629random network of chains that may act as a sieve preventing
630the spread of the bacteria. Platelet concentrate (PC) was
631previously reported to have antimicrobial properties12 signiﬁ-
632cantly reducing the growth of methicillin-sensitive or -resistant
633Staphylococcus aureus, Group A Streptococcus, and Neisseria
634gonorrhea, among others. As PL is a product of PC activation by
635freeze/thaw cycles, the same would be expected for this
636hemoderivative. The obtained results in this study meet with
637the antimicrobial properties already described in the literature
638for platelet concentrates.12 Here, the methicillin resistant
639Staphylococcus aureus (MRSA) was more susceptible to the
640hydrogels containing PL100 than the other microbial strains
641tested. Yeaman and Bayer proposed that the bactericidal
642activity against MRSA involved β-lysin, which is responsible for
643blood clotting found after platelets activation.44,45 β-lysin,
644which is one of the most abundant compound found in PL after
645activation46 has been described to act against bacteria cell-wall,
646rapidly killing and stopping bacteria reproduction,44,45 which
647could explain the results from this study. In addition, other PL-
648derived molecules with antibacterial properties against Gram+
649bacteria could be involved in this response, such as neutrophil
650activating protein-2 demonstrated capacity to kill Gram-positive
651and Gram-negative bacteria.47,48 Although no eﬀect was
652observed against Gram bacteria and fungus, other factors can
653be found in PL with bactericidal and fungicidal activity. For
654instance, Platelet factor-4 can bind to Gram-negative bacteria
655because it has an aﬃnity for the lipopolysaccharide from these
656bacteria, facilitating their clearance.49,50 Nevertheless, further
657investigation is needed in order to fully understand PL
658antimicrobial properties against microbial pathogens, especially
659whether the molecules that demonstrate antimicrobial potential
660interact alone or together when supplemented as PL and not
661from induced platelets.
662■ CONCLUSIONS
663Overall, our ﬁndings demonstrate that is possible to obtain
664versatile photo-cross-linkable HA-PL hydrogels that provide
665adequate substrates for hPDLFs attachment and growth while
666enabling the sustained release of PL and inhibit bacterial
667growth. Besides providing adequate space and stability, as well
668as biochemical cues for the regeneration of the lost tissues the
669hydrogels developed in this study present antimicrobial
670properties, which can contribute for the prophylaxis, preventing
671recurrent microbiotic colonization of the periodontal wound.
672These results suggest the great potential of these materials as
673cell and/or autologous growth factors carriers for endogenous
674regenerative technology (ERT) envisioning tissue engineering
675approaches targeting various tissues, namely the periodontal
676ligament.
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711 ■ ABBREVIATIONS
712 PL, platelet lysate
713 hPDLFs, human periodontal ligament ﬁbroblasts
714 GTR, guided tissue regeneration
715 HAase, hyaluronidase
716 ERT, endogenous regenerative technology
717 MRSA, methicillin -resistant Staphylococcus aureus
718 VRSA, vancomycin-resistant Staphylococcus aureus
719 HA, hyaluronic acid
720 me-HA, methacrylated hyaluronic acid
721 GFs, growth factors
722 α-MEM, minimum essential medium Eagle alpha modiﬁca-
723 tion
724 PDMS, polydimethylsiloxane
725 MA, methacrylic anhydride
726 dH2O, distilled water
727 FTIR, Fourier transform infrared spectroscopy
728
1HNMR, proton nuclear magnetic resonance
729 Dmet, degree of methacrylation
730 PL0, hydrogel incorporating 0 v/v% PL
731 PL50, hydrogel incorporating 50 v/v% PL
732 PL100, hydrogel incorporating 100 v/v% PL
733 HAPL, hyaluronic acid hydrogels incorporating PL
734 mwet, hydrogel wet mass
735 mdry, dry hydrogel mass
736 mi, initial weight
737 mf, ﬁnal weight
738 ELISA, enzyme-linked immunosorbent assay
739 FGF-2, ﬁbroblast growth factor-2
740 MH, Muller−Hinton (agar)
741 DMA, dynamic mechanical analysis
742pI, isoelectric point
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